Axogen (AXGN) Cash & Equivalents (2010 - 2026)

Axogen's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $94.6 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 372.01% year-over-year to $94.6 million; the TTM figure through Jun 2026 stood at $94.6 million (up 372.01% YoY), while the FY2025 annual figure was $35.5 million, up 29.01% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $94.6 million, up from $82.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $94.6 million in Q2 2026, with the low at $7.7 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $19.6 million (2024), against an average of $28.1 million.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents slumped 77.73% in 2022, then jumped 372.01% in 2026.
• Axogen's Cash & Equivalents stood at $15.3 million in 2022, then jumped by 102.98% to $31.0 million in 2023, then retreated by 11.18% to $27.6 million in 2024, then gained by 29.01% to $35.5 million in 2025, then jumped by 166.04% to $94.6 million in 2026.
• Business Quant data shows AXGN's Cash & Equivalents at $94.6 million in Q2 2026, $82.7 million in Q1 2026, and $35.5 million in Q4 2025.